Two New Coronary Drugs Approved for Marketing, Simcere and Junshi Each Wins

On January 29, the official website of the State Drug Administration stated that the State Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the “Drug Administration Law” and in accordance with the special approval procedures for drugs, and conditionally approved the application of Hainan Simcere Pharmaceutical Co., Ltd. Combination packaging of class 1 innovative drug cenotevir tablets/ritonavir tablets (trade name: cenotevir), and class 1 innovative drug deuterium remidevir hydrobromide tablets declared by Shanghai Wangshi Biomedical Technology Co., Ltd. ( Product name: Mendewei) listed. These are the latest two new crown oral drugs approved for marketing in China. So far, five new crown oral drugs have been approved for marketing in China. | Related reading (Chengdu Business Daily)

Nan Gonghua

In addition to the latest two new crown oral drugs, Sennuoxin and Mindevit, five new crown oral drugs have been approved for marketing in China. It’s just that it has only been approved for listing now, which really makes people lament that it is a bit late. No matter what the principle of the drug is, which stage or age group it is suitable for patients to take, these new crown special drugs should be prepared before the epidemic is released.

Now the most dangerous first wave of infection climax has passed. Although there will be more waves of infection in the future, the elderly and patients with underlying diseases who died in the first wave may have accounted for the majority of the total. For the new crown specific drug manufacturers In other words, it also missed the best sales opportunity for drugs.

This article is reproduced from: https://www.fortunechina.com/jingxuan/26371.htm
This site is only for collection, and the copyright belongs to the original author.